Main Menu


Researchers at The Institute of Cancer Research were the first to show that cabazitaxel is effective for treating men with advanced castration-resistant prostate cancer (CRPC) after docetaxel and novel endocrine therapies have stopped working.

Prostate cancer tissue, Mateus Crespo for the ICR

Image: Mateus Crespo/Professor Johann de Bono, the ICR

This research, led by Professor Johann de Bono and published in The Lancet, offers reassurance to men for whom docetaxel and hormone therapy has failed, providing them with another treatment option, which not only prolongs life but also positively impacts quality of life for these patients.